Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEMDNASDAQ:BJDXNASDAQ:GCTKNASDAQ:PSTV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEMDAethlon Medical$1.62+15.7%$2.74$1.40▼$8.44$2.82M1.89183,852 shs179,443 shsBJDXBluejay Diagnostics$1.60$1.78$1.46▼$167.00$2.39M0.38661,351 shs61,887 shsGCTKGlucoTrack$6.21-0.5%$8.55$5.16▼$3,756.00$2.98M-0.1945,296 shs40,838 shsPSTVPlus Therapeutics$0.19+3.9%$0.47$0.16▼$2.31$3.13M0.646.10 million shs120.92 million shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEMDAethlon Medical-11.39%-22.22%-56.02%-58.43%-70.79%BJDXBluejay Diagnostics+2.56%-4.76%-11.60%-58.33%-98.94%GCTKGlucoTrack-1.27%-0.95%-21.98%-59.06%-99.76%PSTVPlus Therapeutics-5.00%-40.34%-38.36%-87.11%-89.76%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEMDAethlon Medical3.12 of 5 stars3.55.00.00.02.30.01.3BJDXBluejay Diagnostics1.1024 of 5 stars0.05.00.00.02.80.00.6GCTKGlucoTrack0.3677 of 5 stars0.05.00.00.00.00.80.0PSTVPlus Therapeutics2.3582 of 5 stars3.34.00.00.02.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEMDAethlon Medical 3.00Buy$56.003,356.79% UpsideBJDXBluejay Diagnostics 0.00N/AN/AN/AGCTKGlucoTrack 0.00N/AN/AN/APSTVPlus Therapeutics 2.50Moderate Buy$11.676,138.86% UpsideCurrent Analyst Ratings BreakdownLatest AEMD, BJDX, PSTV, and GCTK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2025PSTVPlus TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $20.505/5/2025PSTVPlus TherapeuticsD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/5/2025PSTVPlus TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/21/2025PSTVPlus TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$19.00 ➝ $20.003/28/2025PSTVPlus TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/28/2025PSTVPlus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $5.50(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEMDAethlon Medical$570K5.71N/AN/A$17.54 per share0.09BJDXBluejay Diagnostics$250K9.54N/AN/A$10.34 per share0.15GCTKGlucoTrackN/AN/AN/AN/A($983.35) per shareN/APSTVPlus Therapeutics$5.82M0.55N/AN/A($1.52) per share-0.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEMDAethlon Medical-$12.21M-$12.64N/AN/AN/AN/A-153.96%-109.13%6/26/2025 (Estimated)BJDXBluejay Diagnostics-$7.72M-$379.74N/A∞N/AN/A-322.46%-262.96%8/13/2025 (Estimated)GCTKGlucoTrack-$22.60M-$56.60N/A∞N/AN/AN/A-544.87%N/APSTVPlus Therapeutics-$12.98M-$2.94N/AN/AN/A-520.90%N/A-202.73%8/13/2025 (Estimated)Latest AEMD, BJDX, PSTV, and GCTK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/26/2025Q4 2025AEMDAethlon Medical-$0.13N/AN/AN/AN/AN/A5/30/2025Q1 2025PSTVPlus Therapeutics-$0.17-$0.56-$0.39-$1.19$1.11 million$1.06 million5/14/2025Q1 2025GCTKGlucoTrackN/A-$20.40N/A-$0.67N/AN/A5/13/2025Q1 2025BJDXBluejay DiagnosticsN/A-$3.37N/A-$3.37N/AN/A3/31/2025Q4 2024BJDXBluejay Diagnostics-$36.00-$112.37-$76.37-$112.37N/AN/A3/27/2025Q4 2024PSTVPlus Therapeutics-$0.51-$0.67-$0.16-$0.67$1.19 million$1.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEMDAethlon MedicalN/AN/AN/AN/AN/ABJDXBluejay DiagnosticsN/AN/AN/AN/AN/AGCTKGlucoTrackN/AN/AN/AN/AN/APSTVPlus TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEMDAethlon MedicalN/A2.802.80BJDXBluejay DiagnosticsN/A2.712.71GCTKGlucoTrack0.034.854.85PSTVPlus TherapeuticsN/A1.031.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEMDAethlon Medical1.99%BJDXBluejay Diagnostics18.47%GCTKGlucoTrack10.92%PSTVPlus Therapeutics3.28%Insider OwnershipCompanyInsider OwnershipAEMDAethlon Medical1.20%BJDXBluejay Diagnostics0.08%GCTKGlucoTrack12.91%PSTVPlus Therapeutics5.49%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEMDAethlon Medical102.01 million1.99 millionNo DataBJDXBluejay Diagnostics91.49 million1.49 millionNot OptionableGCTKGlucoTrack5480,000416,000Not OptionablePSTVPlus Therapeutics2017.00 million16.07 millionNot OptionableAEMD, BJDX, PSTV, and GCTK HeadlinesRecent News About These CompaniesPlus Therapeutics Restructures Financing to Eliminate Potential Dilution of 1.5 Billion SharesJune 24 at 8:18 AM | quiverquant.comPlus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity FinancingJune 24 at 7:30 AM | globenewswire.comPlus (PSTV) Upgraded to Buy: Here's WhyJune 19, 2025 | zacks.comPlus Therapeutics Modifies Security Holders’ RightsJune 17, 2025 | tipranks.comPlus Therapeutics Reports First Quarter Financial Results and Recent Business HighlightsMay 30, 2025 | finance.yahoo.comPlus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue EstimatesMay 30, 2025 | zacks.comPlus Therapeutics, Inc. Reports Q1 2025 Financial Results and Updates on REYOBIQ™ Trials and CNSide® Assay Platform ProgressMay 30, 2025 | quiverquant.comPlus Therapeutics Reports First Quarter Financial Results and Recent Business HighlightsMay 30, 2025 | globenewswire.comPlus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed ...May 23, 2025 | gurufocus.comPlus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-QMay 23, 2025 | globenewswire.comPlus Therapeutics reports progress in CNS cancer therapyMay 15, 2025 | investing.comPlus Therapeutics’ REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM)May 15, 2025 | finance.yahoo.comPlus Therapeutics (PSTV) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseMay 14, 2025 | zacks.comPlus Therapeutics' REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM)May 14, 2025 | globenewswire.comPlus Therapeutics to Participate in the D. Boral Capital Inaugural Global ConferenceMay 8, 2025 | globenewswire.comD. Boral Capital Downgrades Plus Therapeutics (PSTV)May 5, 2025 | msn.comPlus Therapeutics appoints Kyle Guse to board of directorsApril 23, 2025 | markets.businessinsider.com5 Small Drug Stocks to Buy as Tariff-Related Uncertainty LoomsApril 23, 2025 | zacks.comPlus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of DirectorsApril 23, 2025 | globenewswire.comPlus Therapeutics Appoints Kyle Guse to BoardApril 18, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAEMD, BJDX, PSTV, and GCTK Company DescriptionsAethlon Medical NASDAQ:AEMD$1.62 +0.22 (+15.71%) Closing price 04:00 PM EasternExtended Trading$1.66 +0.04 (+2.22%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation. The company was incorporated in 1999 and is based in San Diego, California.Bluejay Diagnostics NASDAQ:BJDX$1.60 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.61 +0.01 (+0.88%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.GlucoTrack NASDAQ:GCTK$6.21 -0.03 (-0.48%) Closing price 04:00 PM EasternExtended Trading$6.48 +0.27 (+4.35%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GlucoTrack, Inc., a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.Plus Therapeutics NASDAQ:PSTV$0.19 +0.01 (+3.89%) Closing price 04:00 PM EasternExtended Trading$0.19 +0.00 (+1.60%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Microsoft Stock Holds Steady as AI Drives Workforce Shift Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
